REFERENCES
1. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8:S3-8.
2. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol. 2014;11:25-40.
3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235-45.
4. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399–407.
5. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014;29:1010–8.
6. Obeso J, Stamelou M, Goetz C, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32:1264-310.
7. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257-72.
8. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504.
9. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-46.
11. Kim JJ, Vitale D, Véliz Otani D, et al. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease. Nat Genet. 2024;56:27–36.
12. Li B, Zhao G, Li K, et al. Characterizing the expression patterns of Parkinson’s disease associated genes. Front Neurosci. 2021;15:629156.
13. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361:1651-61.
14. Vernay B, Koch M, Vaccarino F, et al. Otx2 regulates subtype specification and neurogenesis in the midbrain. J Neurosci. 2005;25:4856-67.
15. Di Salvio M, Di Giovannantonio LG, Acampora D, et al. Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat Neurosci. 2010;13:1481-8.
16. Frantz G, Weimann J, Levin M, Mcconnell S. Otx1 and Otx2 define layers and regions in developing cerebral cortex and cerebellum. J Neurosci. 1994;14:5725-40.
17. Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A. 2003;100:4245-50.
18. Peng C, Fan S, Li X, et al. Overexpression of pitx3 upregulates expression of BDNF and GDNF in SH‐SY5Y cells and primary ventral mesencephalic cultures. FEBS Lett. 2007;581:1357-61.
19. Peng C, Aron L, Klein R, et al. Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J Neurosci. 2011;31:12802-15.
20. Van Den Munckhof P, Luk KC, Ste-Marie L, et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development. 2003;130:2535-42.
21. Martinat C, Bacci J, Leete T, et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci U S A. 2006;103:2874-9.
22. Semina EV, Ferrell RE, Mintz-Hittner HA, et al. A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD. Nat Genet. 1998;19:167-70.
23. Semina EV. Deletion in the promoter region and altered expression of Pitx3 homeobox gene in aphakia mice. Hum Mol Genet. 2000;9:1575-85.
24. Kouwenhoven WM, Von Oerthel L, Smidt MP. Pitx3 and En1 determine the size and molecular programming of the dopaminergic neuronal pool. PLoS ONE. 2017;12:e0182421.
25. Le W, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2002;33:85-9.
26. Saucedo-Cardenas O, Quintana-Hau JD, Le W, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A. 1998;95:4013-8.
27. Zetterström RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997;276:248-50.
28. Kadkhodaei B, Ito T, Joodmardi E, et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci. 2009;29:15923-32.
29. Laguna A, Schintu N, Nobre A, et al. Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson’s disease. Nat Neurosci. 2015;18:826-35.
30. Sgadò P, Albéri L, Gherbassi D, et al. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proc Natl Acad Sci U S A. 2006;103:15242-7.
31. Wurst W, Auerbach AB, Joyner AL. Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum. Development. 1994;120:2065-75.
32. Wurst W, Prakash N. Wnt1-regulated genetic networks in midbrain dopaminergic neuron development. J Mol Cell Biol. 2013;6:34-41.
33. Zhang J, Götz S, Vogt Weisenhorn DM, Simeone A, Wurst W, Prakash N. A WNT1-regulated developmental gene cascade prevents dopaminergic neurodegeneration in adult En1+/- mice. Neurobiol Dis. 2015;82:32-45.
34. Goodier JL, Kazazian HH. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell. 2008;135:23-35.
35. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-8.
36. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early‐onset parkinsonism. Ann Neurol. 2004;56:336-41.
37. Lin X, Cook TJ, Zabetian CP, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012;2:954.
38. Kedaigle AJ, Fraenkel E, Atwal RS, et al.; The HD iPSC Consortium. Bioenergetic deficits in Huntington’s disease iPSC-derived neural cells and rescue with glycolytic metabolites. Hum Mol Genet. 2020;29:1757-71.
39. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-7.
40. Hu Y, Yang H, Song C, et al. LRRK2G2019S gene mutation causes skeletal muscle impairment in animal model of Parkinson’s disease. J Cachexia Sarcopenia Muscle. 2024;15:2595-607.
41. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469-73.
42. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.
43. Zhuang D, Ren Z, Sheng J, et al. A dynamic nomogram for predicting unfavorable prognosis after aneurysmal subarachnoid hemorrhage. Ann Clin Transl Neurol. 2023;10:1058-71.
44. Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203-12.
45. Goto R, Matsuoka K, Kimura Y, et al. Human biodistribution and radiation dosimetry of two novel α-synuclein PET tracers, 18F-SPAL-T-06 and 18F-C05-05. Sci Rep. 2025;15:8640.
46. Hällqvist J, Bartl M, Dakna M, et al. Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset. Nat Commun. 2024;15:4759.
47. Buhmann C, Magnus T, Choe C. Blood neurofilament light chain in Parkinson’s disease. J Neural Transm. 2023;130:755-62.
48. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388:839-40.
49. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045-7.
50. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302-5.
51. Patek CE. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet. 2003;12:2379-94.
52. Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-9.
53. Paisán-Ruı́z C, Jain S, Evans E, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595-600.
54. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158-60.
55. Morimoto M, Takahashi Y, Endo M, Saga Y. The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity. Nature. 2005;435:354-9.
56. Dell’agnello C, Leo S, Agostino A, et al. Increased longevity and refractoriness to Ca2+-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet. 2007;16:431-44.
57. Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7:583-90.
58. Nörenberg A, Hu H, Vida I, Bartos M, Jonas P. Distinct nonuniform cable properties optimize rapid and efficient activation of fast-spiking GABAergic interneurons. Proc Natl Acad Sci U S A. 2009;107:894-9.
59. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85:257-73.
60. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19:170-8.
61. Andersson ER, Saltó C, Villaescusa JC, et al. Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc Natl Acad Sci U S A. 2013;110:E602-10.
62. Nouri P, Götz S, Rauser B, et al. Dose-dependent and subset-specific regulation of midbrain dopaminergic neuron differentiation by LEF1-mediated WNT1/b-catenin signaling. Front Cell Dev Biol. 2020;8:587778.
63. Yang D, Peng C, Li X, et al. Pitx3‐transfected astrocytes secrete brain‐derived neurotrophic factor and glial cell line‐derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures. J Neurosci Res. 2008;86:3393-400.
64. Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11:1261.
65. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119:866-72.
66. Firestone JA, Smith-Weller T, Franklin G, Swanson P, Longstreth WT, Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol. 2005;62:91.
67. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol. 2009;169:919-26.
68. Pouchieu C, Piel C, Carles C, et al. Pesticide use in agriculture and Parkinson’s disease in the AGRICAN cohort study. Int J Epidemiol. 2018;47:299-310.
69. Hancock DB, Martin ER, Mayhew GM, et al. Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol. 2008;8:6.
70. Liu R, Young MT, Chen J, Kaufman JD, Chen H. Ambient air pollution exposures and risk of Parkinson disease. Environ Health Perspect. 2016;124:1759-65.
71. Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3:1301-6.
72. Goldman SM, Tanner CM, Oakes D, Bhudhihanok GSS, Gupta A, Langston JW. Head injury and Parkinson’s disease risk in twins. Ann Neurol. 2006;60:65-72.
73. Van Maele-Fabry G, Hoet P, Vilain F, Lison D. Occupational exposure to pesticides and Parkinson’s disease: a systematic review and meta-analysis of cohort studies. Environ Int. 2012;46:30-43.
74. Lock EA, Zhang J, Checkoway H. Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence. Toxicol Appl Pharmacol. 2013;266:345-55.
75. Sallmén M, Burstyn I, Uuksulainen S, Koskinen A, Hublin C, Sainio M. Parkinson’s disease and occupational exposure to organic solvents in Finland: a nationwide case-control study. Scand J Work Environ Health. 2024;50:39-48.
76. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson’s disease. Neurology. 1997;48:650-8.
77. Racette BA, Tabbal SD, Jennings D, Good L, Perlmutter JS, Evanoff B. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology. 2005;64:230–35.
78. Kwakye G, Paoliello M, Mukhopadhyay S, Bowman A, Aschner M. Manganese-induced parkinsonism and Parkinson’s disease: shared and distinguishable features. Int J Environ Res Public Health. 2015;12:7519-40.
79. Zeng W, Cai J, Zhang L, Peng Q. Iron deposition in Parkinson’s disease: a mini-review. Cell Mol Neurobiol. 2024;44:26.
80. Krzyzanowski B, Mullan AF, Turcano P, Camerucci E, Bower JH, Savica R. Air pollution and Parkinson disease in a population-based study. JAMA Netw Open. 2024;7:e2433602.
81. Wang VA, Delaney S, Flynn LE, et al. The effect of air pollution on hospitalizations with Parkinson’s disease among medicare beneficiaries nationwide. NPJ Parkinsons Dis. 2024;10:196.
82. Nishiwaki H, Hamaguchi T, Ito M, et al. Short-chain fatty acid-producing gut microbiota is decreased in Parkinson’s disease but not in rapid-eye-movement sleep behavior disorder. mSystems. 2020;5:e00797-20.
83. Chen S, Chen C, Liao H, et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology. 2022;98:e848-58.
84. Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD‐MCI by MDS task force criteria: How many and which neuropsychological tests? Mov Disord. 2014;30:402-6.
85. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66:1824-9.
86. Hashim H, Azmin S, Razlan H, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS ONE. 2014;9:e112330.
87. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010;74:878–84.
88. Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez‐Martin P. Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord. 2011;26:407-15.
89. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta‐analysis. Mov Disord. 2013;28:1222-9.
90. Hernán MA, Takkouche B, Caamaño‐Isorna F, Gestal‐Otero JJ. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276-84.
91. Yue X, Li H, Yan H, Zhang P, Chang L, Li T. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine. 2016;95:e3549.
92. Roth NM, Saidha S, Zimmermann H, et al. Photoreceptor layer thinning in idiopathic Parkinson’s disease. Mov Disord. 2014;29:1163-70.
93. Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol. 2013;12:716–26.
94. Fang X, Han D, Cheng Q, et al. Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2018;1:e182421.
96. GBD 2016 Parkinson’s Disease Collaborators Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939-53.
97. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet. 1989;333:1269.
98. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38:515-7.
99. Monzani E, Nicolis S, Dell’Acqua S, et al. Dopamine, oxidative stress and protein–quinone modifications in Parkinson’s and other neurodegenerative diseases. Angew Chem Int Ed. 2019;58:6512-27.
100. Song D, Li J. Revisiting the advance of age-dependent α-synuclein propagation and aggregation. Ageing Neur Dis. 2025;5:4.
101. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-217.
102. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38:17-28.
104. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl:S4-9.
105. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10:217-24.
106. Bendig J, Frank A, Reichmann H. Aging and Parkinson’s disease: a complex interplay of vulnerable neurons, the immune system and the blood-brain barrier. Ageing Neur Dis. 2024;4:5.
107. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296-302.
108. Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM. Blood–brain barrier leakage is increased in Parkinson’s disease. Front Physiol. 2020;11:593026.
109. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283-301.
110. Branch SY, Sharma R, Beckstead MJ. Aging decreases L-type calcium channel currents and pacemaker firing fidelity in substantia nigra dopamine neurons. J Neurosci. 2014;34:9310-8.
111. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson’s disease. Front Neuroendocrinol. 2014;35:370–84.
113. Jacobs BM, Belete D, Bestwick J, et al. Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry. 2020;91:1046-54.
114. Kwon D, Paul KC, Kusters C, et al. Interaction between traffic-related air pollution and Parkinson disease polygenic risk score. JAMA Netw Open. 2025;8:e250854.
115. Tsalenchuk M, Gentleman SM, Marzi SJ. Linking environmental risk factors with epigenetic mechanisms in Parkinson’s disease. NPJ Parkinsons Dis. 2023;9:123.
116. Angelopoulou E, Piperi C. Epigenetics: the missing link between environmental exposures and Parkinson’s disease? Epigenomics. 2024;16:921-7.
117. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42:781-5.
118. Lindestam Arlehamn CS, Dhanwani R, Pham J, et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun. 2020;11:1875.
119. Yu E, Ambati A, Andersen MS, et al. Fine mapping of the HLA locus in Parkinson’s disease in Europeans. NPJ Parkinsons Dis. 2021;7:84.
120. Noelker C, Morel L, Lescot T, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep. 2013;3:1393.
121. Hughes CD, Choi ML, Ryten M, et al. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis. Acta Neuropathol. 2018;137:103-20.
122. Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349–60.
123. Kim C, Ho D, Suk J, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.
124. Pike AF, Varanita T, Herrebout MAC, et al. α‐Synuclein evokes NLRP3 inflammasome‐mediated IL‐1β secretion from primary human microglia. Glia. 2021;69:1413-28.
125. Lee E, Hwang I, Park S, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2018;26:213-28.
126. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
127. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80:2035-41.
128. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson’s disease. Ann Neurol. 2006;60:197-203.
129. Rietdijk CD, Perez-Pardo P, Garssen J, Van Wezel RJA, Kraneveld AD. Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol. 2017;8:37.
130. Braak H, Tredici KD, Rüb U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197-211.
131. Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis. 2015;1:15013.
132. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-74.
133. Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis. 2017;7:S71-85.
134. Kang X, Ploner A, Wang Y, et al. Genetic overlap between Parkinson disease and inflammatory bowel disease. medRxiv. 2022.
135. Witoelar A, Jansen IE, Wang Y, et al.; for the International Parkinson’s Disease Genomics Consortium (IPDGC), North American Brain Expression Consortium (NABEC), and United Kingdom Brain Expression Consortium (UKBEC) Investigators. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780-92.
136. Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease. Nat Neurosci. 2022;25:588-95.
137. La Manno G, Gyllborg D, Codeluppi S, et al. Molecular diversity of midbrain development in mouse, human, and stem cells. Cell. 2016;167:566-80.e19.
138. Tepe B, Hill MC, Pekarek BT, et al. Single-cell RNA-seq of mouse olfactory bulb reveals cellular heterogeneity and activity-dependent molecular census of adult-born neurons. Cell Rep. 2018;25:2689-703.e3.
139. Kawasawa YI, Salzberg AC, Li M, Sestan N, Greer CA, Imamura F. RNA-seq analysis of developing olfactory bulb projection neurons. Mol Cell Neurosci. 2016;74:78-86.
140. Tremblay C, Aslam S, Walker JE, et al. RNA sequencing of olfactory bulb in Parkinson’s disease reveals gene alterations associated with olfactory dysfunction. Neurobiol Dis. 2024;196:106514.
141. Lu T, Wang M, Zhou W, et al. Decoding transcriptional identity in developing human sensory neurons and organoid modeling. Cell. 2024;187:7374-93.e28.
142. Sharma N, Flaherty K, Lezgiyeva K, Wagner DE, Klein AM, Ginty DD. The emergence of transcriptional identity in somatosensory neurons. Nature. 2020;577:392-8.
143. Han X, Zhou Z, Fei L, et al. Construction of a human cell landscape at single-cell level. Nature. 2020;581:303-9.
144. Rossi LF, Harris KD, Carandini M. Spatial connectivity matches direction selectivity in visual cortex. Nature. 2020;588:648-52.
145. Wright CM, Schneider S, Smith-Edwards KM, et al. scRNA-Seq reveals new enteric nervous system roles for GDNF, NRTN, and TBX3. Cell Mol Gastroenterol Hepatol. 2021;11:1548-92.e1.
146. Beach TG, White CL, Hladik CL, et al.; The Arizona Parkinson’s Disease Consortium. Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 2008;117:169.
147. Duda JE. Olfactory system pathology as a model of Lewy neurodegenerative disease. J Neurol Sci. 2010;289:49-54.
148. Puig J, Pedraza S, Blasco G, et al. Acute damage to the posterior limb of the internal capsule on diffusion tensor tractography as an early imaging predictor of motor outcome after stroke. AJNR Am J Neuroradiol. 2011;32:857-63.
149. Day IN, Thompson RJ. UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol. 2010;90:327-62.
150. Genç B, Lagrimas AKB, Kuru P, et al. Visualization of sensory neurons and their projections in an upper motor neuron reporter line. PLoS ONE. 2015;10:e0132815.
151. Taniguchi K, Harumi S, Okamura M, Ogawa K. Immunohistochemical demonstration of protein gene product 9.5 (PGP 9.5) in the primary olfactory system of the rat. Neurosci Lett. 1993;156:24-6.
152. Kruzich PJ, Grandy DK. Dopamine D2 receptors mediate two-odor discrimination and reversal learning in C57BL/6 mice. BMC Neurosci. 2004;5:12.
153. Zhou H, Zhuang L, Bao H, et al. Olfactory regulation by dopamine and DRD2 receptor in the nose. Proc Natl Acad Sci U S A. 2022;119:e2118570119.
154. Medeiros D, Masini D, Plewnia C, et al. Dopamine D2 receptor activation counteracts olfactory dysfunction and related cellular abnormalities in experimental parkinsonism. Heliyon. 2024;10:e35948.
155. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184-91.
156. Yang X, Xu Y. Mutations in the ATP13A2 gene and parkinsonism: a preliminary review. Biomed Res Int. 2014;2014:371256.
157. Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A. 2012;109:9611-6.
158. Ritz B, Lee P, Hansen J, et al. Traffic-related air pollution and Parkinson’s disease in denmark: a case–control study. Environ Health Perspect. 2016;124:351-6.
159. Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480-4.
161. Fil A, Cano-de-la-Cuerda R, Muñoz-Hellín E, Vela L, Ramiro-González M, Fernández-de-las-Peñas C. Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord. 2013;19:285-94.
162. Taly AB, Muthane UB. Involvement of peripheral nervous system in juvenile Parkinson’s disease. Acta Neurol Scand. 2009;85:272-5.
163. Simchovitz A, Hanan M, Niederhoffer N, et al. NEAT1 is overexpressed in Parkinson’s disease substantia nigra and confers drug‐inducible neuroprotection from oxidative stress. FASEB J. 2019;33:11223-34.
164. Raunio A, Kivistö V, Kero M, et al. Distribution of Lewy-related pathology in the brain, spinal cord, and periphery: the population-based Vantaa 85 + study. Acta Neuropathol Commun. 2022;10:178.
165. Tavares-Ferreira D, Shiers S, Ray PR, et al. Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. Sci Transl Med. 2022;14:eabj8186.
166. Greenbaum L, Tegeder I, Barhum Y, Melamed E, Roditi Y, Djaldetti. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain. 2012;16:1243-50.
167. Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A. 2010;107:5148-53.
168. Habib AM, Okorokov AL, Hill MN, et al. Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br J Anaesth. 2019;123:e249-53.
169. Cajanus K, Holmström EJ, Wessman M, Anttila V, Kaunisto MA, Kalso E. Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer. Pain. 2016;157:361-9.
170. Latremoliere A, Latini A, Andrews N, et al. Reduction of neuropathic and inflammatory pain through inhibition of the tetrahydrobiopterin pathway. Neuron. 2015;86:1393-406.
171. Pan H, Zhao Y, Mei J, et al. GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson’s disease: a two-cohort case-control study. Transl Neurodegener. 2020;9:31.
172. Larbalestier H, Keatinge M, Watson L, et al. GCH1 deficiency activates brain innate immune response and impairs tyrosine hydroxylase homeostasis. J Neurosci. 2022;42:702-16.
173. Franco R, Rivas-Santisteban R, Navarro G, Pinna A, Reyes-Resina I. Genes implicated in familial Parkinson’s disease provide a dual picture of nigral dopaminergic neurodegeneration with mitochondria taking center stage. Int J Mol Sci. 2021;22:4643.
174. Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease. Trends Neurosci. 2019;42:140-9.
175. Smolders S, Van Broeckhoven C. Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson’s disease pathogenesis. Acta Neuropathol Commun. 2020;8:63.
176. Zhang F, Wu Z, Long F, et al. The roles of ATP13A2 gene mutations leading to abnormal aggregation of α-synuclein in Parkinson’s disease. Front Cell Neurosci. 2022;16:927682.
177. Veronesi B, Oortgiesen M. Neurogenic inflammation and particulate matter (PM) air pollutants. Neurotoxicology. 2001;22:795-810.
178. Morarach K, Mikhailova A, Knoflach V, et al. Diversification of molecularly defined myenteric neuron classes revealed by single-cell RNA sequencing. Nat Neurosci. 2020;24:34-46.
179. Beach TG, Adler CH, Sue LI, et al.; Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689-702.
180. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual‐hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599-614.
181. Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1-/- mice. Nature. 2019;571:565-9.
182. Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson’s disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell. 2016;166:314-27.
183. Wallings RL, Tansey MG. LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Trans. 2019;47:1581-95.
184. Singh Y, Trautwein C, Dhariwal A, et al. DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs). Sci Rep. 2020;10:16131.
185. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265-9.
186. Clemson CM, Hutchinson JN, Sara SA, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 2009;33:717-26.
187. Boros FA, Maszlag-Török R, Vécsei L, Klivényi P. Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease. Brain Res. 2020;1730:146672.
188. Walker KL, Yoo HK, Undamatla J, Szaro BG. Loss of neurofilaments alters axonal growth dynamics. J Neurosci. 2001;21:9655-66.
189. Zhu Q, Couillard-Després S, Julien J. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol. 1997;148:299-316.
190. Hansson O, Janelidze S, Hall S, et al.; For the Swedish BioFINDER study. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88:930-7.
191. Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. 2020;16:265-84.
192. Liu Y, Dou K, Xue L, Li X, Xie A. Neurofilament light as a biomarker for motor decline in Parkinson’s disease. Front Neurosci. 2022;16:959261.
193. Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69:1445-52.
194. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet. 1999;23:47-51.
195. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451-2.
196. Mayer RJ, Tipler C, Arnold J, et al. Endosome-lysosomes, ubiquitin and neurodegeneration. Adv Exp Med Biol. 1996;389:261-9.
197. Schultheis PJ, Fleming SM, Clippinger AK, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet. 2013;22:2067-82.
198. Vrijsen S, Besora-Casals L, Van Veen S, et al. ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci U S A. 2020;117:31198-207.
199. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci. 2012;32:4240-6.
200. Fujii T, Nagamori S, Wiriyasermkul P, et al. Parkinson’s disease-associated ATP13A2/PARK9 functions as a lysosomal H+,K+-ATPase. Nat Commun. 2023;14:2174.
201. Ho PWL, Li L, Liu HF, et al. In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson’s disease. Brain Behav. 2023;13:e2886.
202. Kulczyńska-Przybik A, Dulewicz M, Słowik A, et al. The clinical significance of cerebrospinal fluid reticulon 4 (RTN4) levels in the differential diagnosis of neurodegenerative diseases. J Clin Med. 2021;10:5281.
203. Styrpejko DJ, Cuajungco MP. Transmembrane 163 (TMEM163) protein: a new member of the zinc efflux transporter family. Biomedicines. 2021;9:220.
204. Nishioka K, Wider C, Vilariño-Güell C, et al. Association of α-, β-, and γ-synuclein with diffuse Lewy body disease. Arch Neurol. 2010;67:970-5.
205. Aune D, Schlesinger S, Mahamat-Saleh Y, Zheng B, Udeh-Momoh CT, Middleton LT. Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. Eur J Epidemiol. 2023;38:591-604.
206. Chohan H, Senkevich K, Patel RK, et al. Type 2 diabetes as a determinant of Parkinson’s disease risk and progression. Mov Disord. 2021;36:1420-9.
207. Guo M, Wang J, Zhao Y, et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease. Brain. 2020;143:1476-97.
208. Svenningsson P, Wirdefeldt K, Yin L, et al. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase‐4 inhibitors - a nationwide case‐control study. Mov Disord. 2016;31:1422-3.
209. Tang H, Lu Y, Okun MS, et al. Glucagon‐like peptide‐1 receptor agonists and risk of Parkinson’s disease in patients with type 2 diabetes: a population‐based cohort study. Mov Disord. 2024;39:1960-70.
210. Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med. 2024;390:1176-85.
211. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664-75.
212. Vijiaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405:627-36.
213. Kalinderi K, Papaliagkas V, Fidani L. GLP-1 receptor agonists: a new treatment in Parkinson’s disease. Int J Mol Sci. 2024;25:3812.
214. Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson’s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol. 2016;19:pyw047.
215. Matthews DC, Lerman H, Lukic A, et al. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. NeuroImage Clin. 2018;20:572-9.
216. Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546:656–61.
218. Paik S, Kim JK, Silwal P, Sasakawa C, Jo E. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18:1141-60.
219. Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR‐induced NF‐κB activation regulates NLRP3 expression in murine macrophages. FEBS Lett. 2012;586:1022-6.
220. Holm CK, Rahbek SH, Gad HH, et al. Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses. Nat Commun. 2016;7:10680.
221. Nakajima M, Schmitt L, Halassa MM. Prefrontal cortex regulates sensory filtering through a basal ganglia-to-thalamus pathway. Neuron. 2019;103:445-58.e10.
222. Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull. 2017;33:515-25.
223. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s disease. J Neurochem. 2016;139 Suppl:216-31.
224. Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: a Swedish register–based matched-cohort study. Neurology. 2017;88:1996-2002.
225. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14:19-30.
226. Reynoso A, Torricelli R, Jacobs BM, et al. Gene–environment interactions for Parkinson’s disease. Ann Neurol. 2024;95:677-87.
227. Fox SH, Katzenschlager R, Lim SY, et al.; on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee. International Parkinson and movement disorder society evidence‐based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33:1248-66.
228. Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med. 2019;380:315-24.
229. PD Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196-205.
230. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-91.
231. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-8.
233. Weintraub D, Mamikonyan E. Impulse control disorders in Parkinson’s disease. Am J Psychiatry. 2019;176:5-11.
234. Lees AJ, Ferreira J, Rascol O, et al.; for the BIPARK-2 Study Investigators. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197-206.
235. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355:896-908.
236. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141-9.
237. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019;15:234-42.
238. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749-59.
239. Nemade D, Subramanian T, Shivkumar V. An update on medical and surgical treatments of Parkinson’s disease. Aging Dis. 2021;12:1021–35.
240. Richard IH, Mcdermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229-36.
241. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168:1066-74.
242. Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: a randomized controlled trial. Neurology. 2020;94:e1764-73.
243. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509-18.
244. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533-40.
245. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328-35.
246. Seppi K, Ray Chaudhuri K, Coelho M, et al.; the collaborators of the Parkinson’s Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease - an evidence‐based medicine review. Mov Disord. 2019;34:180-98.
247. Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387:421-32.
248. Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591-600.
249. Poewe W, Volc D, Seppi K, et al.; AFF011 study investigators. Safety and tolerability of active immunotherapy targeting α-synuclein with PD03A in patients with early Parkinson’s disease: a randomized, placebo-controlled, phase 1 study. J Parkinsons Dis. 2021;11:1079-89.
250. Heras‐Garvin A, Weckbecker D, Ryazanov S, et al. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2018;34:255-63.
251. Meglio M. Continued progress in phase 1 study of antisense oligonucleotide ION464 in MSA. 2024. Available from: https://www.neurologylive.com/view/continued-progress-phase-1-study-antisense-oligonucleotide-ion464-msa. [Last accessed on 29 Apr 2026].
252. Mullin S, Smith L, Lee K, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77:427.
253. Siemeling O, Slingerland S, Van Der Zee S, Van Laar T. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation. BMC Neurol. 2024;24:146.
254. Nutt JG, Curtze C, Hiller A, et al. Aromatic L‐amino acid decarboxylase gene therapy enhances levodopa response in Parkinson’s disease. Mov Disord. 2020;35:851-8.
255. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum Gene Ther. 2012;23:377-81.
256. Bloem BR, Macklin EA, Schwarzschild MA. GLP-1 agonists to slow down Parkinson’s progression? The quest continues. Med. 2025;6:100645.
257. Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab. 2022;34:396-407.e6.
258. Yamamoto K, Ito H, Fukutake S, Kamei T, Yamaguchi T, Taira T. Ventralis intermedius thalamotomy with focused ultrasound for patients with low skull density ratio. Mov Disord. 2019;34:1239-40.
259. Surace MJ, Block ML. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell Mol Life Sci. 2012;69:2409-27.
260. Geng L, Fan LM, Liu F, Smith C, Li JM. Nox2 dependent redox-regulation of microglial response to amyloid-β stimulation and microgliosis in aging. Sci Rep. 2020;10:1582.
261. ClinicalTrials.gov. A study of AAV2-GDNF in adults with moderate Parkinson’s disease (REGENERATE-PD). Available from: https://clinicaltrials.ucsf.edu/trial/NCT06285643. [Last accessed on 29 Apr 2026].
262. Van Laar AD, Christine CW, Phielipp N, et al. Intraputaminal delivery of adeno-associated virus serotype 2–glial cell line–derived neurotrophic factor in mild or moderate Parkinson’s disease. Mov Disord. 2025;40:1297–306.
263. Tabar V, Sarva H, Lozano AM, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease. Nature. 2025;641:978-83.
264. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657-73.
265. Taymans J, Fell M, Greenamyre T, et al. Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. 2023;9:104.
266. Zhang X, Tang B, Guo J. Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Transl Neurodegener. 2023;12:59.
267. De Sciscio M, Bryant RV, Haylock-Jacobs S, et al. Faecal microbiota transplant in Parkinson’s disease: pilot study to establish safety & tolerability. NPJ Parkinsons Dis. 2025;11:203.
268. Hutchison RM, Fraser K, Yang M, et al. Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial. Neurology. 2024;102:e209137.
269. Wang Y, Li Z, Li J, Sun C. LncRNA NEAT1 promotes MPP+ induced injury of PC12 cells and accelerates the progression of Parkinson’s disease in mice through FUS mediated inhibition of PI3K/AKT/mTOR signalling pathway. Exp Gerontol. 2024;191:112436.
270. Yan W, Chen Z, Chen J, Chen H. LncRNA NEAT1 promotes autophagy in MPTP-induced Parkinson’s disease through stabilizing PINK1 protein. Biochem Biophys Res Commun. 2018;496:1019-24.
271. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007;51:105-11.
272. Osaka H. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet. 2003;12:1945-58.
273. Erb ML, Sipple K, Levine N, Chen X, Moore DJ. Adult-onset deletion of ATP13A2 in mice induces progressive nigrostriatal pathway dopaminergic degeneration and lysosomal abnormalities. NPJ Parkinsons Dis. 2024;10:133.
274. Sikora J, Dovero S, Kinet R, et al. Nigral ATP13A2 depletion induces Parkinson’s disease-related neurodegeneration in a pilot study in non-human primates. NPJ Parkinsons Dis. 2024;10:141.
275. Dehay B, Martinez-Vicente M, Ramirez A, et al. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy. 2014;8:1389-91.
276. Jennings D, Huntwork‐Rodriguez S, Vissers MF, et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson’s disease. Mov Disord. 2023;38:386-98.
277. Ysselstein D, Nguyen M, Young TJ, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients. Nat Commun. 2019;10:5570.
278. Jennings D, Huntwork-Rodriguez S, Henry AG, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease. Sci Transl Med. 2022;14:eabj2658.
279. Cole TA, Zhao H, Collier TJ, et al. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight. 2021;6:e135633.
280. Nakamori M, Junn E, Mochizuki H, Mouradian MM. Nucleic acid–based therapeutics for Parkinson’s disease. Neurotherapeutics. 2019;16:287-98.
281. Gu L, Zhang P, Gao R, Shu H, Wang P. Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson’s disease. Front Aging Neurosci. 2024;16:1465016.
282. Tönges L, Buhmann C, Klebe S, et al. Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. J Neural Transm. 2022;129:1201-17.
283. Rissardo JP, Fornari Caprara AL. Alpha-synuclein seed amplification assays in Parkinson’s disease: a systematic review and network meta-analysis. Clin Pract. 2025;15:107.
284. Brockmann K, Quadalti C, Lerche S, et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun. 2021;9:175.
285. Agin-Liebes J, Lodge A, Reddy H, et al. α-Synuclein biomarker assays: bridging research and patient care. Lancet Neurol. 2025;24:681-97.
286. Wilson J, Yarnall AJ, Craig CE, et al. Cholinergic basal forebrain volumes predict gait decline in Parkinson’s disease. Mov Disord. 2020;36:611-21.
287. Prime M, Mckay JL, Bay AA, et al. Differentiating Parkinson disease subtypes using clinical balance measures. J Neurol Phys Ther. 2020;44:34-41.
288. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715-25.
289. Grosch J, Winkler J, Kohl Z. Early degeneration of both dopaminergic and serotonergic axons - a common mechanism in Parkinson’s disease. Front Cell Neurosci. 2016;10:293.
290. Heng N, Malek N, Lawton MA, et al. Striatal dopamine loss in early Parkinson’s disease: systematic review and novel analysis of dopamine transporter imaging. Movement Disord Clin Pract. 2023;10:539-46.
291. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288-95.
292. Mercer MK, Revels JW, Blacklock LC, et al. Practical overview of 123I-ioflupane imaging in parkinsonian syndromes. Radiographics. 2024;44:e230133.
293. Seckin ZI, Whitwell JL, Utianski RL, et al. Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. J Neurol. 2020;267:2603–11.
294. Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893-9.
295. Madelung CF, Løkkegaard A, Fuglsang SA, et al. High-resolution mapping of substantia nigra in Parkinson’s disease using 7 tesla magnetic resonance imaging. NPJ Parkinsons Dis. 2025;11:113.
296. Lakhani DA, Zhou X, Tao S, et al. Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson’s disease. NPJ Parkinsons Dis. 2024;10:13.
297. Pyatigorskaya N, Sanz-Morère CB, Gaurav R, et al. Iron imaging as a diagnostic tool for Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2020;11:366.
298. Wang Z, Luo X, Gao C. Utility of susceptibility-weighted imaging in Parkinson’s disease and atypical Parkinsonian disorders. Transl Neurodegener. 2016;5:17.
299. Langkammer C, Pirpamer L, Seiler S, et al. Quantitative susceptibility mapping in Parkinson’s disease. PLoS ONE. 2016;11:e0162460.
300. Depierreux F, Parmentier E, Mackels L, et al. Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. NPJ Parkinsons Dis. 2021;7:57.
301. Sun YM, Wang ZY, Liang YY, Hao CW, Shi CH. Digital biomarkers for precision diagnosis and monitoring in Parkinson’s disease. NPJ Digit Med. 2024;7:218.
302. Weirath NA, Hurben AK, Chao C, et al. Small molecule inhibitors of TET dioxygenases: Bobcat339 activity is mediated by contaminating copper(II). ACS Med Chem Lett. 2022;13:792-8.
303. Wiseman JA, Turner CP, Faull RLM, Halliday GM, Dieriks BV. Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy. Transl Neurodegener. 2025;14:7.
304. Kuzkina A, Bargar C, Schmitt D, et al. Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study. NPJ Parkinsons Dis. 2021;7:99.
305. Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331:1298-306.
306. Pedersen CC, Ushakova A, Alves G, et al. Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s disease. NPJ Parkinsons Dis. 2024;10:162.
307. Donadio V, Wang Z, Incensi A, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology. 2021;96:e2513-24.
308. Che N, Huang J, Wang S, et al. The potential use of plasma NfL as a diagnostic and prognostic biomarker of fatigue in early Parkinson’s disease. Ther Adv Neurol Disord. 2025;18:17562864251324406.
309. Iakovakis D, Hadjidimitriou S, Charisis V, Bostantzopoulou S, Katsarou Z, Hadjileontiadis LJ. Touchscreen typing-pattern analysis for detecting fine motor skills decline in early-stage Parkinson’s disease. Sci Rep. 2018;8:7663.
310. Bhidayasiri R, Mari Z. Digital phenotyping in Parkinson’s disease: empowering neurologists for measurement-based care. Parkinsonism Relat Disord. 2020;80:35-40.
311. Tat T, Chen G, Xu J, Zhao X, Fang Y, Chen J. Diagnosing Parkinson’s disease via behavioral biometrics of keystroke dynamics. Sci Adv. 2025;11:eadt6631.
312. Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson’s disease. Mov Disord. 2010;25:1560-7.
313. Gardner RC, Byers AL, Barnes DE, Li Y, Boscardin J, Yaffe K. Mild TBI and risk of Parkinson disease. Neurology. 2018;90:e1771-9.
314. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091-102.
315. Saffie-Awad P, Grant SM, Makarious MB, et al.; Global Parkinson’s Genetics Program (GP2). Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores. NPJ Parkinsons Dis. 2025;11:201.
316. Pereira PAB, Trivedi DK, Silverman J, et al. Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease. NPJ Parkinsons Dis. 2022;8:39.
317. Hu L, Dong M, Huang Y, et al. Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson’s disease. Front Mol Neurosci. 2020;13:80.
318. Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20:415-8.
